Panbela Therapeutics (OTCMKTS:PBLA – Get Free Report) is expected to post its results on Friday, November 13th. Analysts expect Panbela Therapeutics to post earnings of ($2,640.00) per share for the quarter.
Panbela Therapeutics Price Performance
Shares of OTCMKTS PBLA opened at $0.00 on Wednesday. The stock has a 50 day moving average price of $0.01 and a 200 day moving average price of $0.01. Panbela Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.10.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research has centered on treatments that target polyamine metabolism, a biological process associated with tumor growth and cancer progression. Panbela’s lead investigational product has been ivospemin, formerly known as SBP-101, which has been studied in combination with standard treatments for pancreatic ductal adenocarcinoma and other solid tumors. The company has also pursued eflornithine-based programs, including combinations intended to support cancer treatment and prevention strategies.
Featured Stories
- Five stocks we like better than Panbela Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
